SCHEMBL4093369

SCHEMBL4093369

CC(C)(C(=O)O)c1cccc(Cl)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.57
TSHR P16473 2/20 0.57
ALDH1A1 P00352 6/20 0.41
GAA P10253 5/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
AGTR1 P30556 1/20 0.36
KMT2A Q03164 3/20 0.36
GRM5 P41594 1/20 0.34
MEN1 O00255 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAP4K4 O95819 1/20 0.34
PDCD1LG2 Q9BQ51 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11388965 0.84 CYP3A4 (0.55) CYP3A4TSHRALDH1A1GAASMN1; SMN2
SCHEMBL27756870 0.81 CYP3A4 (0.52) CYP3A4TSHRALDH1A1GAASMN1; SMN2
SCHEMBL126954 0.79 RAB9A (0.43) ALDH1A1SMN1; SMN2HPGDKMT2AGRM5
SCHEMBL11391263 0.79 CYP3A4 (0.64) CYP3A4TSHRALDH1A1GAASMN1; SMN2
SCHEMBL126953 0.78 TSHR (0.33) CYP3A4TSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL31216648 0.78 P2RX7 (0.47)
SCHEMBL11395905 0.78 TSHR (0.57) CYP3A4TSHRALDH1A1GAASMN1; SMN2
SCHEMBL3509089 0.78 ALDH1A1 (0.37) TSHRALDH1A1MAPTHPGDKMT2A
SCHEMBL1718131 0.77 CYP3A4 (0.47) CYP3A4TSHRALDH1A1HPGDKMT2A
SCHEMBL30552539 0.76 CYP3A4 (0.59) CYP3A4TSHRALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-26 US disclosed
EP-1995243-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF HSD11B1, HSD11B2, HSD17B1 CYP3A4 219/4885TSHR 1936/4885ALDH1A1 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.